A Phase 2a, Double-blind, Randomized, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Oral Pf-06651600 And Pf-06700841 As Induction And Open Label Extension Treatment In Subjects With Moderate To Severe Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs PF 6651600 (Primary) ; PF 6700841 (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 Mar 2018 Planned End Date changed from 5 Feb 2021 to 18 Feb 2021.
- 07 Mar 2018 Planned primary completion date changed from 22 Jan 2020 to 4 Feb 2020.
- 19 Feb 2018 Status changed from not yet recruiting to recruiting.